search
Back to results

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

Primary Purpose

Coagulopathy, Hemorrhage

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Autologous Spray Dried Plasma
Sponsored by
Velico Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Coagulopathy focused on measuring dried plasma, coagulation function, plasmapheresis

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Males and nonpregnant/nonbreastfeeding females For females, a minimum weight of 140 pounds and maximum weight of 220 pounds; for males, a minimum weight of 140 pounds and a maximum weight of 250 pounds Subject is 18 to 65 years of age, inclusive Subject self-reports that he or she feels well and healthy Subject scores ≥35 on the Duke Activity Status Index Subject is able to donate a unit of plasma by plasmapheresis based on the AABB Donor History Questionnaire with modifications indicated: subjects with history of travel, which puts them at risk for Creutzfeldt-Jakob Disease or malaria, are eligible to participate Subject has completed a vaccination course for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with the final vaccine injection administered at least 2 weeks before enrollment Subject has read the educational materials on donating blood and has had his or her questions answered Subject is able and willing to provide written informed consent Females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation) or should use a highly effective medically accepted contraceptive regimen. Highly effective methods of birth control are defined as those which result in a low failure rate (ie, less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, condoms with spermicide, or vasectomized partner All females must have a negative urine or serum pregnancy test Subject understands the English language Exclusion Criteria: Subject has known liver, kidney, cardiovascular, neurologic, gastrointestinal, blood, endocrine/metabolic, autoimmune, or pulmonary disease, or treated or untreated hypertension Subject has cancer of any kind, under treatment or resolved Subject has known or past coagulopathy conditions Subject has any conditions, uses medications, etc. on the AABB medical deferral list Subject has a history of asthma (defined as use of a prescribed daily asthma controller medication or required asthma medication in the past 2 weeks) Subject has a previous diagnosis of stroke, deep vein thrombosis (DVT), venous or arterial thrombosis, blood clots, or transient ischemic attack Subject has a family history of venous or arterial thrombosis before the age of 50 years in first degree relatives (ie, biological parents, full siblings, or children) Subject has a D-dimer test result ≥0.5 FEU/mL Subject has a recent (within 1 year of Screening) history of an abnormal electrocardiogram of clinical significance as determined by the site PI Subject has known HIV or AIDS-related illness or received a positive test result for HIV infection Subject has a positive test result for HBV, hepatitis C virus (HCV), or human T-cell lymphotropic virus Subject has a history of significant treated or untreated mental health issues Subject is currently taking an antibiotic or another medication for an infection Subject has received aspirin or other platelet-inhibiting agents within 14 days of study donation and infusion visits. Prior and concomitant medication information will be recorded beginning 30 days before enrollment through the final follow-up visit Subject is currently using any medications for anticoagulant therapy Subject has used clotting factor concentrates(s) (eg, FVIIa) Subject has received blood or blood products within the past 12 months Subject has had concurrent headache and fever in the past week Subject has systolic blood pressure (current) greater than 140 mm Hg Subject has diastolic blood pressure (current) greater than 90 mm Hg Subject has an oral temperature greater than 100°F Subject has known hematocrit ≤39% for male donors and ≤38% for female donors Subject has a positive DAT result Subject has received any investigational agent within 1 month before treatment infusion for this study Subject is participating in any phase of any other investigational studies while participating in this study Subject is unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits as scheduled Subject has other unspecified reasons that, in the opinion of the site PI, make the subject unsuitable for enrollment Subject is institutionalized because of legal or regulatory order Subject has a positive urine drug screen

Sites / Locations

  • Hoxworth Blood CenterRecruiting
  • Versiti Blood Center of Wisconsin
  • Spaulding Clinical Research LLC

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Cohort 1

Cohort 2

Cohort 3 Arm 3

Cohort 3 Arm 4

Arm Description

Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 1 unit (200 mL) of autologous FrontlineODP.

Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection, in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 2 units (400 mL) of autologous FrontlineODP.

Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous FrontlineODP and 4 units of autologous control PF24. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 3 will receive 4 units of FrontlineODP during the first infusion visit, and following a 14 day washout period, they would receive 4 units of PF24 during a second visit.

Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous control PF24 and 4 units of autologous FrontlineODP. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 4 will receive 4 units of PF24 during the first infusion visit, and following a 14 day washout period, they would receive 4 units of FrontlineODP during the second visit.

Outcomes

Primary Outcome Measures

Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Conclusions about safety will be based on the occurrence of TEAEs in Cohort 1 (1 unit of FrontlineODP, 200 mL) and Cohort 2 (2 units of FrontlineODP, 400 mL).
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Conclusions about safety will be based on the occurrence of TEAEs in Cohort 3 with infusions of 4 units (800 mL) of FrontlineODP compared to 4 units (800 mL) of PF24.

Secondary Outcome Measures

Changes in PT
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in INR
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in aPTT
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in Factor I
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in Factor II
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in Factor V
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in Factor VII
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in Factor VIII
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in Factor IX
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in Factor X
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in Factor XI
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in D-dimer
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in von Willebrand Ristocetin Cofactor (vWF:RCo) activity
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in von Willebrand (vWF) antigen
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in protein S
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Changes in protein C
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.

Full Information

First Posted
October 28, 2022
Last Updated
October 18, 2023
Sponsor
Velico Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT05629338
Brief Title
Ascending Dose Study of FrontlineODP™ Spray Dried Plasma
Official Title
Evaluation for the Safety of FrontlineODP™ in a Multidose Randomized Cohort Study Compared With PF24
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2022 (Actual)
Primary Completion Date
May 15, 2024 (Anticipated)
Study Completion Date
May 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Velico Medical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study in healthy volunteers is designed to assess the safety of infusing increasing doses of spray dried plasma (FrontlineODP).
Detailed Description
This study in healthy volunteers is designed to assess the safety of infusing increasing doses of spray dried plasma (FrontlineODP). Volunteers will have their plasma collected, spray dried, and then rehydrated for infusion. Volunteers will be infused with their own (autologous) rehydrated plasma. Cohort 1 will receive 1 FrontlineODP unit that is rehydrated to approximately 200 mL. Cohort 2 will receive 2 FrontlineODP units of approximately 400 mL. Cohort 3 volunteers will receive 2 separate infusions of 4 units of approximately 800 mL of either FrontlineODP (experimental) or frozen plasma (PF24). Order of receipt of plasma product will be randomized with 14 days between infusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coagulopathy, Hemorrhage
Keywords
dried plasma, coagulation function, plasmapheresis

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Model Description
This study in healthy volunteers (n=24) is designed to assess the safety of infusing ascending doses of reconstituted autologous FrontlineODP in 1, 2, and 4 fixed-dose units. Subjects in Cohort 1 (n = 6) will receive 1 unit of FrontlineODP (Arm 1), which is approximately 200 mL. Subjects in Cohort 2 (n = 6) will receive 2 FrontlineODP units (Arm 2) (total volume of approximately 400 mL). Cohort 3 is a crossover design where subjects (n = 12) will be randomly assigned to receive either 4 units of FrontlineODP followed 14 days later by 4 units of PF24 (Arm 3 - ODPxPF24), or 4 units of PF24 followed 14 days later by 4 units of FrontlineODP (Arm 4 - PF24xODP), where each infusion has a total volume of approximately 800 mL.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
For Cohorts 1 and 2, blinding is not necessary because subjects will only receive a single infusion of FrontlineODP. Cohort 3 subjects will be randomly assigned to a treatment sequence and will remain blinded to the study product they receive at each visit. Study participants, the Principal Investigators, the Independent Medical Monitor, and the Data Monitoring Committee will be blinded to the randomization treatment assignments throughout the study.
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 1 unit (200 mL) of autologous FrontlineODP.
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection, in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 2 units (400 mL) of autologous FrontlineODP.
Arm Title
Cohort 3 Arm 3
Arm Type
Active Comparator
Arm Description
Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous FrontlineODP and 4 units of autologous control PF24. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 3 will receive 4 units of FrontlineODP during the first infusion visit, and following a 14 day washout period, they would receive 4 units of PF24 during a second visit.
Arm Title
Cohort 3 Arm 4
Arm Type
Active Comparator
Arm Description
Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous control PF24 and 4 units of autologous FrontlineODP. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 4 will receive 4 units of PF24 during the first infusion visit, and following a 14 day washout period, they would receive 4 units of FrontlineODP during the second visit.
Intervention Type
Combination Product
Intervention Name(s)
Autologous Spray Dried Plasma
Other Intervention Name(s)
FrontlineODP Unit, Frontline On Demand Plasma Unit
Intervention Description
Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers
Primary Outcome Measure Information:
Title
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Description
Conclusions about safety will be based on the occurrence of TEAEs in Cohort 1 (1 unit of FrontlineODP, 200 mL) and Cohort 2 (2 units of FrontlineODP, 400 mL).
Time Frame
Start of plasma infusion through 28 day follow up (Day 29).
Title
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Description
Conclusions about safety will be based on the occurrence of TEAEs in Cohort 3 with infusions of 4 units (800 mL) of FrontlineODP compared to 4 units (800 mL) of PF24.
Time Frame
Start of first plasma infusion through 28 day follow up of the second infusion (Day 43).
Secondary Outcome Measure Information:
Title
Changes in PT
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in INR
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in aPTT
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in Factor I
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in Factor II
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in Factor V
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in Factor VII
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in Factor VIII
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in Factor IX
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in Factor X
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in Factor XI
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in D-dimer
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in von Willebrand Ristocetin Cofactor (vWF:RCo) activity
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in von Willebrand (vWF) antigen
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in protein S
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).
Title
Changes in protein C
Description
changes between pre-infusion baseline and 4 hours post-infusion values after infusion of 4 units of FrontlineODP compared with infusion of the same dose of PF24.
Time Frame
Start of first plasma infusion through 28-day follow up of second infusion (Day 43).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Males and nonpregnant/nonbreastfeeding females For females, a minimum weight of 140 pounds and maximum weight of 220 pounds; for males, a minimum weight of 140 pounds and a maximum weight of 250 pounds Subject is 18 to 65 years of age, inclusive Subject self-reports that he or she feels well and healthy Subject scores ≥35 on the Duke Activity Status Index Subject is able to donate a unit of plasma by plasmapheresis based on the AABB Donor History Questionnaire with modifications indicated: subjects with history of travel, which puts them at risk for Creutzfeldt-Jakob Disease or malaria, are eligible to participate Subject has completed a vaccination course for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with the final vaccine injection administered at least 2 weeks before enrollment Subject has read the educational materials on donating blood and has had his or her questions answered Subject is able and willing to provide written informed consent Females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation) or should use a highly effective medically accepted contraceptive regimen. Highly effective methods of birth control are defined as those which result in a low failure rate (ie, less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, condoms with spermicide, or vasectomized partner All females must have a negative urine or serum pregnancy test Subject understands the English language Exclusion Criteria: Subject has known liver, kidney, cardiovascular, neurologic, gastrointestinal, blood, endocrine/metabolic, autoimmune, or pulmonary disease, or treated or untreated hypertension Subject has cancer of any kind, under treatment or resolved Subject has known or past coagulopathy conditions Subject has any conditions, uses medications, etc. on the AABB medical deferral list Subject has a history of asthma (defined as use of a prescribed daily asthma controller medication or required asthma medication in the past 2 weeks) Subject has a previous diagnosis of stroke, deep vein thrombosis (DVT), venous or arterial thrombosis, blood clots, or transient ischemic attack Subject has a family history of venous or arterial thrombosis before the age of 50 years in first degree relatives (ie, biological parents, full siblings, or children) Subject has a D-dimer test result ≥0.5 FEU/mL Subject has a recent (within 1 year of Screening) history of an abnormal electrocardiogram of clinical significance as determined by the site PI Subject has known HIV or AIDS-related illness or received a positive test result for HIV infection Subject has a positive test result for HBV, hepatitis C virus (HCV), or human T-cell lymphotropic virus Subject has a history of significant treated or untreated mental health issues Subject is currently taking an antibiotic or another medication for an infection Subject has received aspirin or other platelet-inhibiting agents within 14 days of study donation and infusion visits. Prior and concomitant medication information will be recorded beginning 30 days before enrollment through the final follow-up visit Subject is currently using any medications for anticoagulant therapy Subject has used clotting factor concentrates(s) (eg, FVIIa) Subject has received blood or blood products within the past 12 months Subject has had concurrent headache and fever in the past week Subject has systolic blood pressure (current) greater than 140 mm Hg Subject has diastolic blood pressure (current) greater than 90 mm Hg Subject has an oral temperature greater than 100°F Subject has known hematocrit ≤39% for male donors and ≤38% for female donors Subject has a positive DAT result Subject has received any investigational agent within 1 month before treatment infusion for this study Subject is participating in any phase of any other investigational studies while participating in this study Subject is unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits as scheduled Subject has other unspecified reasons that, in the opinion of the site PI, make the subject unsuitable for enrollment Subject is institutionalized because of legal or regulatory order Subject has a positive urine drug screen
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lisa Buckley, MPH
Phone
978-232-8370
Ext
1707
Email
lbuckley@veli.co
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Popovsky, MD
Organizational Affiliation
Velico Medical
Official's Role
Study Director
Facility Information:
Facility Name
Hoxworth Blood Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267-0055
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neeta Rugg
First Name & Middle Initial & Last Name & Degree
Jose Cancelas
Facility Name
Versiti Blood Center of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53233
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anglea Treml, MD
First Name & Middle Initial & Last Name & Degree
Angela Treml, MD
Facility Name
Spaulding Clinical Research LLC
City
West Bend
State/Province
Wisconsin
ZIP/Postal Code
53095
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan Matousek, DO
First Name & Middle Initial & Last Name & Degree
Jan Matousek, DO

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

We'll reach out to this number within 24 hrs